Form 8-K - Current report:
SEC Accession No. 0000950170-24-097206
Filing Date
2024-08-14
Accepted
2024-08-14 17:15:06
Documents
13
Period of Report
2024-08-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eldn-20240814.htm   iXBRL 8-K 48455
2 EX-99.1 eldn-ex99_1.htm EX-99.1 23793
3 GRAPHIC img20068692_0.jpg GRAPHIC 11376
  Complete submission text file 0000950170-24-097206.txt   209941

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eldn-20240814.xsd EX-101.SCH 24851
16 EXTRACTED XBRL INSTANCE DOCUMENT eldn-20240814_htm.xml XML 4703
Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36620 | Film No.: 241209526
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)